Hyperaldosteronism
Recent clinical, regulatory, research and industry developments relating to this disease.
Subclinical Primary Aldosteronism and Cardiovascular Health: A Population-Based Cohort Study.
What's happening now
An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.
- 2 clinical trials expected to report results, the earliest in Q3 2027.
- Q3 2027A Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Efficacy and Safety of Baxdrostat in Adult Participants With Primary Aldosteronism
- Q4 2027Phase 2 Study Evaluating the Functional Status of the Adrenal Glands With [68Ga]Ga-PentixaFor in Hyperaldosteronism and Hypercortisolism
Clinical MilestonesViewHide
- 2026-07-06A Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Efficacy and Safety of Baxdrostat in Adult Participants With Primary AldosteronismResults expected Q3 2027
- 2026-06-29Phase 2 Study Evaluating the Functional Status of the Adrenal Glands With [68Ga]Ga-PentixaFor in Hyperaldosteronism and HypercortisolismResults expected Q4 2027
- 2026-07-06ClinicalA Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Efficacy and Safety of Baxdrostat in Adult Participants With Primary AldosteronismResults expected Q3 2027
- 2026-06-29ClinicalPhase 2 Study Evaluating the Functional Status of the Adrenal Glands With [68Ga]Ga-PentixaFor in Hyperaldosteronism and HypercortisolismResults expected Q4 2027
- 2026-03-03ClinicalA Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, and Effectiveness of CIN-107 for the Management of Blood Pressure in Patients With Primary AldosteronismResults posted
- 2025-12-31ClinicalA Prospective Randomized Controlled Trial for Treatment of Idiopathic Hyperaldosteronism: Superselective Adrenal Arterial Embolization Versus Oral SpironolactonePrimary completion
Clinical trials
The current development programme across all trial phases.
Research activity
Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.
Major themes3
- Cardiovascular Diseases1
- Hyperaldosteronism1
- Hypertension1
Leading journals1
- Circulation1
Leading researchers8
- Agharazii M1
- Brown JM1
- Crean AM1
- Goupil R1
- Hametner B1
- Hiremath S1
- Hundemer GL1
- Kline GA1
Affiliations (unnormalised)6
- Brigham and Women's Hospital1
- Center for Adrenal Disorders1
- Center for Health & Bioresources1
- CHU de Québec-Université Laval1
- Clinical Epidemiology Program1
- Cumming School of Medicine1
Associated genes
Genes associated with this disease in the canonical knowledge graph (Open Targets evidence). Number shows the association score.
Reference
Authoritative identity, definition & identifiers.
A condition caused by the overproduction of ALDOSTERONE. It is characterized by sodium retention and potassium excretion with resultant HYPERTENSION and HYPOKALEMIA.
- Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
- Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
- Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
- Related entities are derived from literature co-mention (studied together) — associative, not causal.